Clinicopathologic features of patients and tumor responses to H pylori eradication
. | Complete remission . | No remission . | P . |
|---|---|---|---|
| No. patients (%) | 37 (61.6) | 23 (38.4) | NS |
| Age, y | |||
| Median (range) | 57 (35-84) | 56 (36-74) | NS |
| Sex, no. (%) | |||
| Male | 15 (40.5) | 11 (47.8) | NS |
| Female | 22 (59.5) | 12 (52.2) | |
| Stage by EUS and CT, no. (%) | |||
| Mucosa/submucosa | 26 (70.3) | 16 (69.6) | NS |
| Muscularis propria/serosa | 11 (29.7) | 7 (30.4) | |
| API2-MALT1, no. (%) | |||
| Positive | 1 (2.7) | 12 (52.2) | < .001 |
| Negative | 36 (97.3) | 11 (47.8) | |
| BCL10 expression, no. (%) | |||
| Cytoplasmic | 34 (91.9) | 3 (13.1) | < .001 |
| Nuclear/cytoplasmic | 3 (8.1) | 20 (86.9) | |
| NF-κB expression, no. (%) | |||
| Cytoplasmic | 34 (91.9) | 4 (17.4) | < .001 |
| Nuclear/cytoplasmic | 3 (8.1) | 19 (82.6) |
. | Complete remission . | No remission . | P . |
|---|---|---|---|
| No. patients (%) | 37 (61.6) | 23 (38.4) | NS |
| Age, y | |||
| Median (range) | 57 (35-84) | 56 (36-74) | NS |
| Sex, no. (%) | |||
| Male | 15 (40.5) | 11 (47.8) | NS |
| Female | 22 (59.5) | 12 (52.2) | |
| Stage by EUS and CT, no. (%) | |||
| Mucosa/submucosa | 26 (70.3) | 16 (69.6) | NS |
| Muscularis propria/serosa | 11 (29.7) | 7 (30.4) | |
| API2-MALT1, no. (%) | |||
| Positive | 1 (2.7) | 12 (52.2) | < .001 |
| Negative | 36 (97.3) | 11 (47.8) | |
| BCL10 expression, no. (%) | |||
| Cytoplasmic | 34 (91.9) | 3 (13.1) | < .001 |
| Nuclear/cytoplasmic | 3 (8.1) | 20 (86.9) | |
| NF-κB expression, no. (%) | |||
| Cytoplasmic | 34 (91.9) | 4 (17.4) | < .001 |
| Nuclear/cytoplasmic | 3 (8.1) | 19 (82.6) |
EUS indicates endoscopic ultrasonography; CT, computed tomography; NS, not significant.